XML 64 R24.htm IDEA: XBRL DOCUMENT v3.20.1
Note 16 - Segment Data
 12 Months Ended
Mar. 31, 2020
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]
Note
16.
  Segment Data
 
Segment information is prepared on the same basis that our CEO, who is our Chief Operating Decision Maker, manages the segments, evaluates financial results, and makes key operating decisions. We have
four
reportable segments: Sterilization and Disinfection Control, Instruments, Biopharmaceutical Development, and Continuous Monitoring (formerly Cold Chain Monitoring). When determining the reportable segments, we aggregated operating segments based on their similar economic and operating characteristics. During the year ended
March 31, 2020,
we exited the Cold Chain Packaging business, which resulted in Management ceasing to consider its results in its analysis of financial results and operational decision making. As of
March 31, 2020,
we
no
longer consider it a reportable segment. Results for the Cold Chain Packaging division are now presented within Corporate and Other and prior period amounts related to Cold Chain Packaging have been categorized and presented as Corporate and Other. The following tables set forth our segment information:
 
   
Year Ended March 31, 2020
  
   
Sterilization and Disinfection Control
    
Instruments
    
Biopharmaceutical Development
    
Continuous Monitoring
    
Corporate and Other
    
Total
  
Revenues (1)
   $
49,660
     $
37,984
     $
13,851
     $
13,729
     $
2,463
     $
117,687
  
Gross profit (loss)   $
35,758
     $
24,229
     $
382
     $
4,146
     $
418
     $
64,933
  
Reconciling items (2)
    
 
      
 
      
 
      
 
      
 
      
(61,500
 )
Earnings before income taxes
    
 
      
 
      
 
      
 
      
 
     $
3,433
  
 
   
Year Ended March 31, 2019
  
   
Sterilization and Disinfection Control
    
Instruments
    
Biopharmaceutical Development
    
Continuous Monitoring
    
Corporate and Other
    
Total
  
Revenues (1)
   $
46,297
     $
36,125
     $
--
     $
13,806
     $
6,907
     $
103,135
  
Gross profit
   $
31,861
     $
22,866
     $
--
     $
5,582
     $
607
     $
60,916
  
Reconciling items (2)
    
 
      
 
      
 
      
 
      
 
      
(52,293
 )
Earnings before income taxes
    
 
      
 
      
 
      
 
      
 
     $
8,623
  
 
   
Year Ended March 31, 2018
  
   
Sterilization and Disinfection Control
    
Instruments
    
Biopharmaceutical Development
    
Continuous Monitoring
    
Corporate and Other
    
Total
  
Revenues (1)
   $
43,260
     $
34,104
     $
--
     $
12,978
     $
5,837
     $
96,179
  
Gross profit
   $
29,333
     $
20,395
     $
--
     $
3,854
     $
1,037
     $
54,619
  
Reconciling items (2)
    
 
      
 
      
 
      
 
      
 
      
(54,318
 )
Earnings before income taxes
    
 
      
 
      
 
      
 
      
 
     $
301
  
 
 
(
1
)
Intersegment revenues are
not
significant and are eliminated to arrive at consolidated totals.
 
(
2
)
Reconciling items include selling, general and administrative, research and development, impairment of goodwill and long-lived assets, legal settlement, and nonoperating expenses.
 
We evaluate the performance of our operating segments based on revenues, organic revenues growth, and gross margin. The accounting policies of the operating segments are the same as those described in Note
1.
"Description of Business and Summary of Significant Accounting Policies." The identifiable assets by segment disclosed in this note are those assets specifically identifiable within each segment and include inventories, accounts receivable, property, plant and equipment, net, right-of-use leased assets directly attributable to operating segments, goodwill, and intangible assets. Assets
not
attributed to reportable operating segments are corporate assets and are primarily comprised of cash and cash equivalents, assets related to our selling, general, and administrative functions, right-of-use assets related to selling, general and administrative functions, and prepaid income taxes. 
 
The following table sets forth capital expenditures by reportable segment:
 
   
Sterilization and Disinfection Control
    
Instruments
    
Biopharmaceutical Development
    
Continuous Monitoring
    
Corporate and Other
    
Total
  
Year ended March 31, 2020
   $
291
     $
165
     $
233
     $
201
     $
608
     $
1,498
  
Year ended March 31, 2019
    
384
      
56
      
--
      
254
      
568
      
1,262
  
Year ended March 31, 2018
    
1,007
      
254
      
--
      
483
      
1,055
      
2,799
  
 
The following table sets forth depreciation and amortization by reportable segment:
 
   
Sterilization and Disinfection Control
    
Instruments
    
Biopharmaceutical Development
    
Continuous Monitoring
    
Corporate and Other
    
Total
  
Year ended March 31, 2020
   $
902
     $
179
     $
358
     $
328
     $
11,223
     $
12,990
  
Year ended March 31, 2019
    
902
      
207
      
--
      
272
      
8,047
      
9,428
  
Year ended March 31, 2018
    
823
      
263
      
--
      
327
      
8,058
      
9,471
  
 
The following table sets forth total assets by reportable segment:
 
   
March 31, 2020
    
March 31, 2019
  
Sterilization and Disinfection Control
   $
73,103
     $
74,230
  
Instruments
    
31,025
      
30,911
  
Biopharmaceutical Development
    
182,758
      
--
  
Continuous Monitoring
    
29,732
      
32,179
  
Corporate and Other
    
103,588
      
19,447
  
Total
   $
420,206
     $
156,767
  
 
The following table sets forth a summary of long-lived assets by geographic area. Long-lived assets exclude goodwill and intangible assets acquired in a business combination. 
 
   
As of March 31,
  
   
2020
    
2019
  
United States
   $
34,767
     $
22,974
  
Foreign
    
1,240
      
574
  
Total long-lived assets
   $
36,007
     $
23,548
  
 
 
Revenues from external customers are attributed to individual countries based upon locations to which the product is shipped or exported, as follows:
 
   
Year Ended March 31,
  
   
2020
    
2019
    
2018
  
United States
   $
66,344
     $
64,828
     $
56,998
  
Foreign
    
51,343
      
38,307
      
39,181
  
Total revenues
   $
117,687
     $
103,135
     $
96,179
  
 
Revenues are shown based on the geographic location of our customers. 
No
customer accounts for
10%
or more of our revenues.
No
foreign country exceeds
10%
 of total revenues.